I went through all 142 companies in Value Line this morning. Here are the 6 that made it
Six Value Line small caps including Blackbaud, Marqeta, Ranger Energy and Definitive Healthcare trade on net cash, buybacks, low multiples or a takeover bid.
Six Value Line small caps including Blackbaud, Marqeta, Ranger Energy and Definitive Healthcare trade on net cash, buybacks, low multiples or a takeover bid.
There is so much demand for compute that $APLD is suing Character AI (now Google) because they claim they couldn't repurpose all of the GPUs they bought to service Character AI https://t.co/sM59vJAuck
Thought there was ample supply still parked on balance sheet in April $NVDA @eliav https://t.co/SaEkbWG311 https://t.co/4ffaSSMwXH
$CRCT Covid fad DIY crafting printers—accelerating unit sales decline, cutting prices. High margin subscription rev (online templates library free elsewhere) now churning off. Set for Q2 miss/ guide down on 8/5. 18-20x P/E. Massive CEO selling. https://t.co/V86UTJv2Np
As #copper industry execs talk of the greatest trade they've ever seen, its interesting to see that my recently published Euro-listed copper idea is the top performing name in the sector since I published it, alongside $FCX, --> $NDA $NDA.GR 👇 https://t.co/3kyp2k7VWl https://t.co/Kjp3Hlssgb
@RicksCEO Market doesn’t care about tariffs anymore. BBB signed. How much stock are we buying tomorrow ? What clubs are we buying? $rick
@oraclealexx @qlixontop @RicksCEO I think $rick has been public since 1995 or smthg. The opty to trade bmb/ re for buyback in future earnings diwn here is tremendous or more m&a…..
$HELE doing what it does best...Massive miss and even bigger guide down. Of course they're stripping out this huge goodwill impairment from 'adjusted EPS', which we won't do. Stock getting clocked, as it should. We've been short since over $100. CH11 is not off the table here...
Free Recaps of the best new stock ideas, delivered every morning.
CoreWeave’s rising debt yields and fading confidence in AI data-center economics frame a weekly review of Meta, Tesla, SpaceX, Netflix,…
CoreWeave's financial statements point to a business model familiar to the authors after a closer review of the AI infrastructure company.
Bloom Energy’s Q3 FY26 revenue rose 138% to $1.24 billion as datacenter power orders lifted operating margin to 18%; capex drove $181…
Philip Morris reported Q3 growth across heated tobacco, combustibles and e-vapor in Europe while gaining U.S. nicotine-pouch share.
Amazon’s Trainium3 adds native PyTorch training support, targeting CUDA-trained researchers with standard APIs, eager mode and…
Alphabet's Gemini 4 Argon aims to undercut rival AI models using proprietary TPUs, while Android, Siri and Google Cloud distribution…
CoreWeave’s $35 billion to $39 billion 2026 spending plan relies on debt as unsecured yields reach 15%, making its GPU cloud expansion a…
Spotify's third-quarter results met or exceeded guidance, with 306 million Premium subscribers and €672 million operating income, while…
Alphabet, Amazon, Meta and Microsoft plan nearly $800 billion of AI infrastructure spending, testing whether incremental returns can stay…
TSOH Weekly Roundup covers Ally’s improving credit and capital returns, Pepsi’s weak beverage brands, and Match Group’s plan to revive…
Texas Instruments reported Q3 revenue of $6.06 billion, up 28%, with 47% operating margin and Q4 guidance above seasonal norms; Cestrian…
ERock’s modular microgrids bridge data-center power gaps years before grid interconnects, with Meta and Anthropic projects filling capacity…
Medpace authorized $1 billion of buybacks through 2028 after Q3 revenue rose 8.5% to $716 million; service revenue grew roughly 12% as…
Lockheed Martin's Q3 missile sales rose 24% on PAC-3, THAAD, GMLRS and PrSM ramps, lifting Missiles and Fire Control backlog to $142.5…
Franco-Nevada, Wheaton and Texas Pacific Land built royalty and streaming businesses by buying fixed shares of mines and wells, tracing the…
Oscar Health raised 2026 operating earnings guidance to $600 million-$800 million after ACA-marketplace expansion drove 60% membership and…
PYPD · long PolyPid, an $80 million Israeli biotech, fell nearly 30% despite solving a clinical problem.
Have a source we’re missing? Send your pick
Every publication on this site, hand-picked.
Every account on this site, hand-picked.
Ordered by how often our editor reaches for them.
Anything we’re missing?
Send us a pick